In contrast, exogenously applied IGFBP2 has been reported to inhibit in vitro and in vivo tumor growth (57), which is in line with IGF-II inhibition suppressing the growth of breast cancer xenografts (29). This evidence concerns the gene IGFBP2 and breast carcinoma.